精神在线您现在的位置:  >> NaSSA合理应用文献研究平台 >> 文献服务 >> 抑郁、焦虑与睡眠障碍 >> 综述文献 >> 文献正文
一篇三步曲实例综述,强调米氮平在降低许多药物引起的焦虑、激越、失眠、抑郁和性功能障碍的临床和药物应用
文献服务】【告诉好友】【打印此文】【关闭窗口
题目(Title)A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction

著者(Authors)】 Barkin RL, Chor PN, Braun BG, Schwer WA.
来源(Source)】 Prim Care Companion J Clin Psychiatry. 1999 Oct;1(5):142-145
关键词(Keywords)】 Mirtazapine,Anxiety,Agitation,Insomnia,Depression,Sexual Dysfunction

摘要(Abstract)】:

BACKGROUND: Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), is characterized by a unique receptor-specific pharmacologic profile and tolerable side-effect profile in comparison to other antidepressants. It has been reported to have a low incidence of agitation, anxiety, and insomnia, which may be due to blockade of 5-HT(2) and 5-HT(3) receptors. This unique multireceptor-mediated clinical pharmacologic profile may reduce the need for polypharmacy in selected patients.

CASE REPORTS: Three cases are presented. In case 1, mirtazapine was able to rapidly treat anxiety and agitation in a 90-year-old woman. This was confirmed with 3 consecutive challenges with mirtazapine. In case 2, both a mood disorder and insomnia were successfully treated with rapid resolution in a patient by using mirtazapine. In case 3, the patient experienced sexual dysfunction while receiving sertraline and developed insomnia with the addition of bupropion. The addition of mirtazapine and the discontinuation of sertraline and bupropion resolved the sexual dysfunction and insomnia. Polypharmacy interventions were decreased in these patients through receptor-specific events from mirtazapine.

CONCLUSION: The new antidepressant mirtazapine appears to be an effective strategy for treating anxiety, agitation, and insomnia and for diminishing SSRI-related sexual dysfunction without compromising the patient's therapeutic response to the medication while decreasing the need for additional pharmacotherapies. More than 70% of patients with major depression will have anxiety symptoms. The 5-HT(2) receptor seems to play a major role in the regulation of anxiety. The anxiolytic properties of mirtazapine may be due to its antagonism of 5-HT(2) receptors and can appear as early as the first week of treatment.


  • 上一篇文献:
  • 下一篇文献:

  • 相关文献
    米氮平引起帕金森病人快速动眼期睡眠行为障碍
    抗抑郁药与射精:米氮平与帕罗西汀固定剂量下的双盲随机对照研究
    交互式电讯记录不同剂量给药方案下米氮平对病人警觉和睡眠的影响
    米氮平对于抑郁症病人睡眠连续性和结构急性效应的初步研究
    米氮平对抑郁症患者睡眠多导图变量的影响
    米氮平,但非氟伏沙明,使抑郁症患者对可乐定治疗的变钝的REM睡眠反应标准化:抑郁症患者α-2肾上腺素受体低敏感性的意义
    米氮平对于睡眠影响的由青年健康志愿者参加的安慰剂对照双盲研究
    睡眠生理测定条件下米氮平和氟西汀对重性抑郁伴有失眠病人的效应比较
    米氮平治疗抑郁症患者期间其睡眠结构、睡眠脑电波分光光谱组成、皮质醇、促肾上腺皮质激素、生长激素、泌乳素、褪黑激素、生长激素释放肽和…
    米氮平的耐受性和安全性
    服用米氮平的抑郁症门诊患者的性功能状况
    米氮平所治疗患者的性功能改变:与抑郁症患者有关的一项国际化多中心的前瞻性观察研究的原始数据



    精神在线网 复旦大学医学院精神卫生学系 合办
    本站专业医学信息和服务仅供中国医疗专业人士参考

    © 精神在线网 PsyCard.Com
    精神/心理医学专业信息网络平台、博客、论坛
    全站文章索引-SiteMap